During the past decade, Dres. Herold/Kaa conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Dres. Herold/Kaa" are "Pulmonary Disease, Chronic Obstructive" (2 trials). Many other conditions were trialed in "Dres. Herold/Kaa" in a lesser frequency.

Most popular intervention types in "Dres. Herold/Kaa" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist" (1 trials), "Spiolto® Respimat®" (1 trials) and "Triple combination of Free or fixed Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist + inhalative corticosteroids" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dres. Herold/Kaa" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Dres. Herold/Kaa". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Dres. Herold/Kaa, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dres. Herold/Kaa, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".